BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold
We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
These 3 Stocks Are Down to Start 2025. What's Going On?
Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the airwaves by Motley Fool analyst David Meier. David, thanks for joining me today.
Moderna spikes as Oracle’s Larry Ellison touts AI-driven mRNA vaccines
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.
Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
Is Moderna Stock a Buy?
Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...
Hosted on MSN6d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.